IM Cannabis (IMCC) investor relations material

Company overview and business model

• International medical-cannabis operator focused on Israel; activities include sourcing, importing, distributing and selling compliant products to pharmacies and authorized distributors.

• Israeli operations include two licensed pharmacies, home delivery, an online retail platform, logistics, brand management and proprietary genetics maintained through third-party cultivators; no large-scale cultivation facilities.

• Germany-focused operations were sold following a September 29, 2026 closing; C$3.0 million in advance payments was the stated consideration, with resources redirected to retained Israeli operations.

Financial performance and metrics

• Cash and cash equivalents were C$1.617 million as of June 30, 2026, on an actual basis.

• July–September 2026 PIPE notes had US$700,000 aggregate principal and generated US$630,000 gross proceeds at 90% of principal; notes bear 8% annual interest, rising to 14% upon default.

• September 2026 registered direct offering sold 655,000 shares at US$2.00; gross proceeds were approximately US$1.31 million before expenses.

• As of October 7, 2026, 1,647,494 common shares were outstanding; full conversion and exercise of the registered securities could increase that count to 4,408,146.

Use of proceeds and capital allocation

• US$630,000 gross proceeds from the PIPE notes had been received by the prospectus date; net proceeds from those issuances are intended for general corporate purposes.

• No proceeds from selling registered shares go to the issuer; cash proceeds may arise from exercise of PIPE, creditor pre-funded and October settlement warrants and are intended for general corporate purposes.

• Net proceeds from the September 2026 registered direct offering are intended for working capital and general corporate purposes, including evaluation of additional business opportunities.